ARTICLE | Clinical News

Effector begins Phase II trial of eFT508 plus Bavencio

November 3, 2017 4:50 AM UTC

Effector Therapeutics Inc. (San Diego, Calif.) began a Phase II trial of eFT508 with or without PD-L1 inhibitor Bavencio avelumab (MSB0010718C, PF-06834635) to treat microsatellite stable colorectal cancer (CRC). Part one of the open-label, U.S. trial will evaluate escalating doses of twice-daily oral eFT508 plus 10 mg/kg IV Bavencio every 2 weeks to determine the dose for part two. The primary endpoint is safety in the first part and and overall response rate (ORR) in the second part. The partners expect interim data from the trial in mid-2018.

eFT508 is a small molecule inhibitor of MAP kinase interacting serine-threonine kinase 1 (MKNK1; MNK1) and MKNK2 (MNK2). It is in Phase I/II testing to treat advanced solid tumors and lymphoma...